BBBinav Baral

Binav Baral

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Binav Baral has a total of 52 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Durable response to tipifarnib in a patient with refractory head and neck cancer with a HRAS mutation: A case report

    by Jennifer J Gile, Katharine Price, Binav Baral, Thomas E Witzig

    Introduction: Head and neck squamous cell carcinoma (HNSCC) remains a clinically challenging malignancy, particularly in the recurrent or metastatic setting after progression on multimodality therapy. Activating health reimbursement arrangement (HRAS) mutations occur in approximately 4–8% of HNSCC and represent a potentially actionable target. Tipifarnib, an oral farnesyltransferase inhibitor, has demonstrated promising activity in HRAS-mutant tumors but is not commercially available despite prior Breakthrough Therapy designation. Case Report: We report the case of a 48-year-old woman with recurrent, treatment-refractory oral cavity squamous cell carcinoma who experienced a dramatic and durable response to tipifarnib. Following initial treatment, she developed rapid locoregional recurrence requiring tracheostomy. Her disease progressed through multiple lines of therapy. Comprehensive next-generation sequencing of recurrent tumor tissue revealed an HRAS mutation. Given lack of response to prior checkpoint inhibitors, compassionate use of tipifarnib was initiated. The patient experienced a near-complete response within two months and achieved a complete response by 12 months and continues to remain disease free almost two years after therapy initiation with excellent functional recovery and manageable toxicity limited primarily to neutropenia. Conclusion: This case highlights the transformative potential of precision oncology in refractory HNSCC. Broader access to HRAS-targeted therapies and prospective validation of molecular predictors are urgently needed to improve outcomes in this molecularly defined subset.

  • Phase II Trial of Pemetrexed and Pembrolizumab in Patients With Recurrent and/or Metastatic Nonadenoid Cystic Salivary Gland Cancer

    by Katharine Andress Rowe Price, Nathan Foster, Erik Asmus, Harry Fuentes-Bayne, Casey Fazer-Posorske, Jordan Meyers, Panayiotis Savvides, Yujie Zhao, Patrick McGarrah, Anna Nguyen, et al.

    PURPOSE: Treatment options for patients with recurrent/metastatic (R/M) salivary gland cancer (SGC) are limited. Limited preclinical and clinical data suggested benefit of pemetrexed in patients with R/M SGC but, to our knowledge, no prospective data exist. We conducted a phase II trial of the combination of pemetrexed and pembrolizumab in patients with R/M SGC; results from the nonadenoid cystic carcinoma (ACC) cohort are reported. PATIENTS AND METHODS: MC200708 is a phase II study of pemetrexed and pembrolizumab in patients with R/M SGC (ClinicalTrials.gov identifier: NCT04895735 ). Simon's two-stage design was used. Any number of prior therapies were allowed. Primary end point was overall response rate (ORR). Secondary end points included progression-free survival (PFS), overall survival (OS), and toxicity. All patients received pemetrexed 500 mg/m 2 IV once every 3 weeks and pembrolizumab 200 mg IV once every 3 weeks until progression or treatment intolerance. RESULTS: Twenty-five patients were enrolled; 24 were eligible and treated. Nine of 24 patients had a confirmed response for ORR of 37.5% (95% CI, 18.8 to 59.4). The ORR for patients with salivary duct carcinoma (SDC) was 63.6%. Median duration of response was 15.3 months (95% CI, 12.4 to not reached). Median OS was 20.0 months (95% CI, 17.1 to not reached) and median PFS was 6.2 months (95% CI, 2.1 to 17.3). One-year OS and PFS rates were 71.9% (95% CI, 55.0 to 94.0) and 36.1% (95% CI, 21.0 to 62.2), respectively. Seven patients (29.2%) had ≥1 grade 3 to 4 toxicity, the majority hematologic. The five patients with grade 3 to 4 nonhematologic toxicity had grade 3 fatigue, rash, heart failure, hematuria, mastoiditis, and hypokalemia. CONCLUSION: Pemetrexed and pembrolizumab has promising and durable activity in patients with R/M SGC, with notable responses in patients with SDC.

  • Open Access

    Real-World Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma: Treatment Delivery, Immune Reconstitution, and Cardiac Monitoring During High-Dose IL-2

    by Mohamed A. Aboelatta, Jabra Zarka, Nika Tchatchua, Noureldin A. Aboelatta, Jeffrey E. Johnson, James W. Jakub, Justin Desroches, Justine Wilson-Miller, Anthony Tabiim, Deepti Behl, et al.

    Background/Objectives: Tumor-infiltrating lymphocyte (TIL) therapy is an important option for patients with metastatic melanoma progressing after standard systemic therapy, but real-world data on treatment delivery, toxicity monitoring, and immune recovery remain limited. We evaluated clinical outcomes, treatment tolerance, immune reconstitution, and cardiac biomarker dynamics across three Mayo Clinic sites. Methods: We retrospectively analyzed adults with metastatic melanoma who received lymphodepleting chemotherapy followed by TIL infusion and high-dose interleukin-2 (IL-2) between April 2024 and December 2025. Clinical outcomes, treatment delivery, and adverse events were assessed. Longitudinal immune monitoring included CD4 and CD8 T-cell counts, CD4:CD8 ratio, and immunoglobulin G (IgG) at baseline and follow-up. In a prespecified cardiac sub-cohort, high-sensitivity troponin (hs-Tn) was measured during IL-2 administration to evaluate associations with cardiac events and IL-2 interruption. Results: Thirty-six patients underwent TIL infusion. The objective response rate was 50.0%, including complete responses in 13.9%, and the disease control rate was 72.2%. Median progression-free survival was 3.61 months, and median overall survival was 12.94 months. M1d disease was associated with inferior overall survival on univariable analysis (HR 6.55, 95% CI 2.03–21.17; p = 0.002), with attenuation after multivariable adjustment. Receipt of ≥3 IL-2 doses was associated with longer overall survival on univariable analysis (HR 0.20, 95% CI 0.06–0.64; p = 0.007), but this association also attenuated after adjustment. Longitudinal immune monitoring demonstrated persistent CD4 lymphopenia through 6 months, sustained inversion of the CD4:CD8 ratio, and declining IgG at months 3 and 6. In the cardiac sub-cohort (24 patients; 87 IL-2 doses), post-dose hs-Tn ≥15 ng/L was associated with clinically significant cardiac events (OR 9.6, 95% CI 1.5–60.6; p = 0.016) and IL-2 interruption (OR 3.4, 95% CI 1.1–10.7; p = 0.036). For cardiac events, hs-Tn ≥15 ng/L had 100% sensitivity and 100% negative predictive value. Conclusions: In routine practice, TIL therapy was feasible and active in metastatic melanoma. M1d disease identified a subgroup with poor survival, peri-dose hs-Tn showed promise as a tool to support safer IL-2 delivery, and prolonged CD4 suppression with IgG decline suggests that recovery after TIL therapy extends beyond initial hematologic reconstitution. These findings support prospective validation of biomarker-guided IL-2 monitoring and extended post-treatment immune surveillance.

  • Open Access

    Induction Cisplatin, Docetaxel, and 5-Fluorouracil Versus Platinum Doublet in Human Papillomavirus-Associated Oropharyngeal Cancer

    by Ashwin Ganti, Patrick W. McGarrah, Harry Fuentes Bayne, Casey Fazer-Posorske, Binav Baral, Daniel J. Ma, Scott C. Lester, David M. Routman, Michelle A. Neben-Wittich, Jessica M. Wilson, et al.

    Management of locoregionally advanced human papillomavirus-positive oropharyngeal squamous cell carcinoma (HPV(+) OPSCC) can include induction chemotherapy followed by definitive chemoradiation. The standard induction regimen of cisplatin, docetaxel, and 5-fluorouracil (TPF) is associated with high toxicity. Given the chemosensitivity of HPV(+) OPSCC, platinum doublets are frequently used as induction therapy with potentially less toxicity. This retrospective study aimed to compare outcomes between treatment-naive HPV(+) OPSCC patients receiving induction TPF and those receiving an induction platinum doublet. Data collected included tumor characteristics, response after chemoradiation, hospitalization rates, and overall survival (OS). Fifty-five patients (18 TPF and 37 platinum doublet) were included. There was no significant difference in response after completion of definitive chemoradiation (TPF: CR 83.3%, PR 5.6%, progression or metastasis 11.1% vs. platinum doublet: CR 75.7%, PR 16.2%, progression or metastasis 8.1%; p = 0.5241). There were also no differences in hospitalizations for adverse events (38.9% in TPF vs. 40.5% in platinum doublet, p = 0.907) or recurrence (11.1% in TPF vs. 2.7% in platinum doublet, p = 0.198). The 5-year OS was 84.6% in the TPF group and 81.5% in the platinum doublet group (p = 0.581). Induction platinum doublet regimens offer comparable OS, response, and hospitalization rates to TPF in locally advanced HPV(+) OPSCC. Induction with a platinum doublet may be a viable de-escalation strategy for patients who are not candidates for TPF.

  • Open Access

    CDX2 Expression and Fluoropyrimidine Response in Rare Non-GI Tumors: A Three-Case Series

    by Riham Suleiman, Andrea Dipp Garcia, Binav Baral, Thorvardur Halfdanarson, Harry Fuentes-Bayne

    Caudal type homeobox 2 (CDX2) is an intestine-specific transcription factor that serves as a diagnostic marker of enteric differentiation and may also reflect tumor behavior and therapeutic susceptibility. Emerging evidence suggests that CDX2 expression may predict sensitivity to fluoropyrimidine-based therapy independent of tissue of origin. We report a retrospective case series of three patients with metastatic adenocarcinoma (aggressive variant prostate, minor salivary gland, and intestinal-type sinonasal tract) exhibiting strong CDX2 nuclear expression. In all cases, tumors were refractory to or lacked established standard systemic therapy. Treatment decisions were informed by the CDX2-positive enteric phenotype, leading to the initiation of fluoropyrimidine-based regimens. Response was assessed using PET-CT and MRI. All three patients achieved marked metabolic and clinical responses, including a sustained complete metabolic response in the prostate cancer case and durable disease control in the salivary gland and sinonasal tumors. These findings highlight CDX2 as a potential biomarker requiring validation, which may identify tumors intrinsically susceptible to fluoropyrimidines regardless of anatomical origin. CDX2 immunohistochemistry is widely available and inexpensive, and may complement genomic profiling in rare malignancies or in settings where standard treatment algorithms are limited. This report is hypothesis-generating and not intended to estimate response rates or treatment efficacy.

  • Open Access

    CDX2 Expression Predicts Fluoropyrimidine Sensitivity Across Rare Non-GI Tumors: A Three-Case Series

    by Riham Suleiman, Andrea Dipp Garcia, Binav Baral, Thorvardur R. Halfdanarson, Harry E. Fuentes Bayne

    Caudal type homeobox 2 (CDX2) is an intestine-specific transcription factor that serves as a diagnostic marker of enteric differentiation and may also reflect tumor behavior and therapeutic susceptibility. Emerging evidence suggests that CDX2 expression may predict sensitivity to fluoropyrimidine-based therapy independent of tissue of origin. We report a retrospective case series of three patients with metastatic adenocarcinoma (aggressive variant prostate, minor salivary gland, and intestinal-type sinonasal tract) exhibiting strong CDX2 nuclear expression. In all cases, tumors were refractory to or lacked established standard systemic therapy. Treatment decisions were guided by the CDX2-positive enteric phenotype, leading to the initiation of fluoropyrimidine-based regimens. Response was assessed using PET-CT and MRI. All three patients achieved marked metabolic and clinical responses, including a sustained complete metabolic response in the prostate cancer case and durable disease control in the salivary gland and sinonasal tumors. These findings highlight CDX2 as a clinically actionable biomarker that may identify tumors intrinsically susceptible to fluoropyrimidines regardless of anatomical origin. CDX2 immunohistochemistry is widely available and inexpensive, and may complement genomic profiling in rare malignancies or in settings where standard treatment algorithms are limited.